Clinical Trials
3
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
EASE (Efficacy of ATX01 Study in Erythromelalgia)
- Conditions
- Erythromelalgia
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- AlgoTherapeutix
- Target Recruit Count
- 14
- Registration Number
- NCT05917912
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇩🇪Universitätsklinikum Erlangen Hautklinik, Erlangen, Germany
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Drug: ATX01 15%Drug: ATX01 10%Drug: Placebo
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- AlgoTherapeutix
- Target Recruit Count
- 276
- Registration Number
- NCT05593614
- Locations
- 🇺🇸
South Lake Pain Institute, Clermont, Florida, United States
🇺🇸MGM Medical Care Research & Rehab, LLC, Miami, Florida, United States
🇺🇸Medsol Clinical Research Center, Inc, Port Charlotte, Florida, United States
News
Cancer Pain Market Poised for Transformation with Novel Non-Opioid Therapies by 2034
The cancer pain therapeutics market is expected to experience significant growth by 2034, driven by increasing cancer incidence and the anticipated launch of breakthrough non-opioid therapies.
AlgoTx's Phase 2 CIPN Trial Shows Promise for ATX01 Despite Placebo Effect Challenges
AlgoTx completed a 276-patient Phase 2 trial evaluating ATX01, a novel topical treatment for chemotherapy-induced peripheral neuropathy, showing encouraging efficacy signals at 15% concentration.